Pharmanutra
Pharmanutra S.p.A., headquartered in Italy, is a leading player in the nutraceutical and pharmaceutical industry, specialising in the development of innovative dietary supplements and medical devices. Founded in 2003, the company has achieved significant milestones, including the introduction of its flagship product, SiderAL, which is renowned for its unique formulation of iron and its high bioavailability. With a strong presence in Europe and expanding operations in international markets, Pharmanutra is committed to enhancing health and well-being through scientifically-backed solutions. The company’s core offerings, including SiderAL and other mineral-based supplements, are distinguished by their patented technologies and rigorous clinical research. Recognised for its excellence, Pharmanutra continues to solidify its market position as a trusted provider of high-quality health products, contributing to advancements in nutritional science.
DitchCarbon Score
How does Pharmanutra's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharmanutra's score of 31 is lower than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmanutra's reported carbon emissions
In 2023, Pharmanutra reported total carbon emissions of approximately 1,086,984 kg CO2e, comprising 229,189 kg CO2e from Scope 1, 270,515 kg CO2e from Scope 2, and 751,110 kg CO2e from Scope 3 emissions, which include significant contributions from business travel and employee commuting. The previous year, 2022, saw total emissions of about 1,042,870 kg CO2e, with Scope 1 emissions at 199,150 kg CO2e, Scope 2 at 88,699 kg CO2e, and Scope 3 emissions of approximately 122,311 kg CO2e. This indicates a rise in emissions from 2022 to 2023, highlighting the challenges Pharmanutra faces in managing its carbon footprint. Pharmanutra has not publicly committed to specific reduction targets or initiatives, nor have they aligned with the Science Based Targets initiative (SBTi). The absence of defined reduction strategies suggests a need for enhanced climate commitments within the industry context. As a company headquartered in Italy, Pharmanutra's emissions data reflects broader trends in corporate sustainability efforts, underscoring the importance of establishing measurable climate goals to mitigate environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 92,590 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 61,095 | 00,000 | 00,000 | 000,000 |
| Scope 3 | - | - | 000,000.00 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pharmanutra is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
